In vitro and in vivo antibacterial studies of volatile oil from Atractylodis Rhizoma against Staphylococcus pseudintermedius and multidrug resistant Staphylococcus pseudintermedius strains from canine pyoderma

Xie, Tong; Lin, Jing; Lin, Degui; Zhang, Di; Xu, Xudong; Zhu, Nailiang; Lin, Jiahao

doi:10.1016/j.jep.2023.117326

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a 14-day treatment with NZ2114, the skin tissue of the mice basically returned to its normal state, indicating that NZ2114 treatment could accelerate the recovery process of the mouse skin. In addition, other antibiotic alternatives derived from plant extracts, such as Aloe vera extract, volatile oil from Atractylodis Rhizoma (VOAR), and Piper betle leaf extract, also showed good therapeutic potential in staphylococcal pyoderma [47][48][49]. Dogs' pyoderma treated with A. vera gel ointment had low haptoglobin and tumor necrosis factor-α concentrations than gentamicin [47].…”

Section: Discussionmentioning

confidence: 99%

“…Dogs' pyoderma treated with A. vera gel ointment had low haptoglobin and tumor necrosis factor-α concentrations than gentamicin [47]. VOAR can significantly reduce the skin bacterial load and has good therapeutic effect on mouse pyoderma induced by S. pseudintermedius [48]. Although these new treatment methods are still in the experimental stage, they have shown great potential, and can provide a pharmacological data reference for the development of new drugs for treating canine pyoderma in the future.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro/Vivo Mechanisms of Antibacterial Peptide NZ2114 against Staphylococcus pseudintermedius and Its Biofilms

Zhang,

Yang,

Mao

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Staphylococcus pseudintermedius is an opportunistic pathogen commonly found in canines, and has garnered escalating interest due to its potential for zoonotic transmission and increasing antimicrobial resistance. However, the excessive use of antibiotics and the characteristic of S. pseudintermedius forming biofilms make treatment challenging. In this study, the in vivo and in vitro antimicrobial activity and mechanisms of action of NZ2114, a plectasin-derived peptide, against S. pseudintermedius were investigated. NZ2114 exhibited potent antibacterial activity towards S. pseudintermedius (minimum inhibitory concentration, MIC = 0.23 μM) with a lower probability of inducing drug-resistant mutations and efficient bactericidal action, which was superior to those of mopirucin (MIC = 0.25–0.5 μM) and lincomycin (MIC = 4.34–69.41 μM). The results of electron microscopy and flow cytometry showed that NZ2114 disrupted S. pseudintermedius’ cell membrane, resulting in cellular content leakage, cytoplasmic membrane shrinkage, and, eventually, cell death. The intracellular ROS activity and Alamar Blue detection showed that NZ2114 interferes with intracellular metabolic processes. In addition, NZ2114 effectively inhibits biofilm formation, and confocal laser scanning microscopy further revealed its antibacterial and anti-biofilm activity (biofilm thickness reduced to 6.90–17.70 μm). The in vivo therapy of NZ2114 in a mouse pyoderma model showed that it was better than lincomycin in effectively decreasing the number of skin bacteria, alleviating histological damage, and reducing the skin damage area. These results demonstrated that NZ2114 may be a promising antibacterial candidate against S. pseudintermedius infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

In Vitro/Vivo Mechanisms of Antibacterial Peptide NZ2114 against Staphylococcus pseudintermedius and Its Biofilms

Zhang,

Yang,

Mao

et al. 2024

Antibiotics

View full text Add to dashboard Cite

show abstract

Antimicrobial Strategies Proposed for the Treatment of S. pseudintermedius and Other Dermato-Pathogenic Staphylococcus spp. in Companion Animals: A Narrative Review

Stefanetti,

Passamonti,

Rampacci

2024

Veterinary Sciences

View full text Add to dashboard Cite

The treatment of dermato-pathogenic Staphylococcus spp., particularly Staphylococcus pseudintermedius, in companion animals presents significant challenges due to rising antimicrobial resistance. This review explores innovative strategies to combat these infections. We examined novel antimicrobials and the repurposing of existing drugs to enhance their efficacy against resistant strains. Additionally, we evaluate the potential of natural products, nanomaterials, and skin antiseptics as alternative treatments. The review also investigates the use of antimicrobial peptides and bacteriophages, highlighting their targeted action against staphylococcal pathogens. Furthermore, the role of adjuvants in antibiotic treatments, such as antimicrobial resistance breakers, is discussed, emphasizing their ability to enhance therapeutic outcomes. Our analysis underscores the importance of a multifaceted approach in developing effective antimicrobial strategies for companion animals, aiming to mitigate resistance and improve clinical management of staphylococcal skin infections.

show abstract

In vitro and in vivo antibacterial studies of volatile oil from Atractylodis Rhizoma against Staphylococcus pseudintermedius and multidrug resistant Staphylococcus pseudintermedius strains from canine pyoderma

Cited by 2 publications

References 30 publications

In Vitro/Vivo Mechanisms of Antibacterial Peptide NZ2114 against Staphylococcus pseudintermedius and Its Biofilms

In Vitro/Vivo Mechanisms of Antibacterial Peptide NZ2114 against Staphylococcus pseudintermedius and Its Biofilms

Antimicrobial Strategies Proposed for the Treatment of S. pseudintermedius and Other Dermato-Pathogenic Staphylococcus spp. in Companion Animals: A Narrative Review

Contact Info

Product

Resources

About